Research advances in the treatment of liver failure with mesenchymal stem cell-derived exosomes.
10.3760/cma.j.cn51113-20220406-00171
- VernacularTitle:间充质干细胞源性外泌体治疗肝衰竭的研究进展
- Author:
Qiu Min LUO
1
;
Shu ZHU
1
;
Liang PENG
1
;
Zhi Liang GAO
1
Author Information
1. Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- Publication Type:Review
- MeSH:
Cell- and Tissue-Based Therapy;
Exosomes;
Hepatic Insufficiency;
Humans;
Liver Failure/therapy*;
Liver Failure, Acute/therapy*;
Mesenchymal Stem Cells
- From:
Chinese Journal of Hepatology
2022;30(3):249-252
- CountryChina
- Language:Chinese
-
Abstract:
Liver failure is a serious clinical syndrome in which multiple pathogenic factors exceed the liver's self-repair capability, resulting massive hepatocellular necrosis, rapid disease progression and high mortality. Liver transplantation is the most effective method for the treatment of liver failure, but it has disadvantages, such as insufficient liver donor and high cost. The clinical efficacy of mesenchymal stem cells in liver failure have been validated, but its application has been limited to certain extent. Cell-free-based therapies, especially mesenchymal stem cell-derived exosomes, has become a research hotspot in recent years. This paper reviews the research advances in the treatment of liver failure with the use of mesenchymal stem cell-derived exosomes.
